Treatment options for patients with malignant pleural mesothelioma (MPM) are limited. While patients with advanced or inoperable MPM are traditionally treated with cisplatin and pemetrexed as a standard first-line treatment, […] Read more

As more data emerge and more investigational drugs are studied, the “undruggable” target is coming into focus. Read more

Lung cancer is the leading cause of cancer mortality worldwide, with an estimated 2.1 million new cases and 1.8 million deaths in 2018—more than colon, breast, and prostate cancers combined.1 […] Read more

The identification of activating EGFR mutations and ALK and ROS1 rearrangements has ushered in an era of precision medicine for advanced NSCLC characterized by swift advances and adaptive drug development. […] Read more

October 2, 2020, saw the first U.S. Food and Drug Administration approval of a drug combination for malignant pleural mesothelioma in 16 years, since the combination cisplatin and pemetrexed was […] Read more

Identification of driver oncogenes in NSCLC is leading the method for accurate patient selection and proper targeting of actionable alterations. Several molecular events have been described, and different biomarkers are […] Read more

Therapies for NSCLC have evolved over the past 2 decades to account for the specific biology of the tumor and have improved outcomes for a multitude of patients. Discovery of […] Read more

Speaking as a medical oncologist who cares for patients with lung cancer, the present is filled with much hope. There has been a profusion of studies that report increasingly improved […] Read more

Immune checkpoint inhibitors (ICIs) and molecular targeting drugs used against oncogenic drivers, such as EGFR or ALK, have dramatically changed the treatment of NSCLC.1-6 However, treatment options after those drugs […] Read more